Translational Neuroendocrinology

Faculty of Medicine | Lund University

Menu

Publications

2017

Gorges M, Vercruysse P, Müller HP, Huppertz HJ, Rosenbohm A, Nagel G, Weydt P, Petersén Å, Ludolph AC, Kassubek J and Dupuis L.
Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis.
Journal of  Neurology, Neurosurgery and Psychiatry. Jun 8  [Epub ahead of print] (2017) 

Follin C, Fjalldal S, Svärd D, van Westen D, Gabery S, Petersén Å, Lätt J, Rylander L and Erfurth EM.
Microstructure alterations in the Hypothalamus in cranially radiated Childhood Leukemia survivors but not in Craniopharyngioma patients unaffected by hypothalamic damage.
Clinical Endocrinology May 14 [Epub ahead of print] (2017) 

Kirik D, Cederfjäll E, Halliday G and Petersén Å.
Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.
Neurobiology of Disease 97: 179-188 (2017)

2016

Soylu-Kucharz R, Baldo B and Petersén Å.
Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease.
Scientific Reports 6: 28322 (2016)

Wagner L, Björkqvist M, Hult Lundh S, Wolf R, Börgel A, Schlenzig D, Ludwig HH, Rahfeld JU,  Leavitt B, Demuth HU, Petersén Å and von Hörsten S.
Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
Journal of Neurochemistry 137(5): 820-37 (2016)

Rochel B, Domínguez D J F, Stout J, Gabery S, Churchyard A, Chua P, Egan G, Petersén A, Georgiou-Karistianis N and Poudel G R.
Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function.
Journal of the Neurological Sciences 364: 148-153 (2016)

Follin C, Gabery S, Petersén Å, Sundgren PC, Björkman-Burtcher I, Lätt J, Mannfolk P and Erfurth EM.
Associations between Metabolic Risk Factors and the Hypothalamic Volume in Childhood Leukemia Survivors Treated with Cranial Radiotherapy.
PLoS One. Jan 29;11(1):e0147575 (2016)

2015

Soylu-Kucharz R, Adlesic N, Baldo B, Kirik D and Petersén Å.
Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue.
Sci Rep. Sep 30;5:14598 (2015)

Wagner L, Wolf R, Zeitschel U, Rossner S, Petersén Å, Leavitt BR, Kästner F, Rothermundt M, Gärtner UT, Gündel D, Schlenzig D, Frerker N, Schade J, Manhart S, Rahfeld JU, Demuth HU and von Hörsten S.
Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.
J Neurochem. 135(5): 1019-37 (2015)

Lilja Andersson P, Petersén Å, Graff C and Edberg A-K.
Ethical aspects of a predictive test for Huntington’s Disease: A long term perspective.
Nursing Ethics. Apr 21 (2015)

Gabery S, Halliday G, Kirik D, Englund E, Petersén Å.
Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study.
Neuropathol Appl Neurobiol. 41(6): 843-848 (2015)

Gabery S, Georgiou-Karistianis N, Lundh SH, Cheong RY, Churchyard A, Chua P, Stout JC, Egan GF, Kirik D and Petersén Å.
Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study.
PLoS One 10(2) (2015)

Wiesner D, Sinniger J, Henriques A, Dieterlé S, Müller H, Rasche V, Ferger B, Dirrig-Grosch S, Soylu-Kucharz R, Petersén A, Walther P, Linkus B, Kassubek J, Wong PC, Ludolph AC and Dupuis L.
Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein mediated neurodegeneration.
Human Molecular Genetics 24(8): 2228-2240 (2015)

Baldo B and Petersén Å.
Analysis of nonmotror features in murine models of Huntington disease
In MS LeDoux (Ed): Movement Disorders 35: 584-597. Elsevier (2015)

2014

Baldo B, Cheong RY and Petersén Å.
Effects of Deletion of Mutant Huntingtin in Steroidogenic Factor 1 Neurons on the Psychiatric and Metabolic Phenotype in the BACHD Mouse Model of Huntington Disease.
PLoS One 9(10) (2014)

Hyrskyluoto A, Bruelle C, Lundh SH, Do HT, Kivinen J, Rappou E, Reijonen S, Waltimo T, Petersén Å, Lindholm D and Korhonen L.
Ubiquitin specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1α.
Human Molecular Genetics 23: 5928-5939 (2014)

Petersén Å and Kirik D.
Twisting mice move the dystonia field forward.
Journal of Clinical Investigation 17: 1-3 (2014)

2013

Baldo B, Soylu R and Petersén Å.
Maintenance of Basal Levels of Autophagy in Huntington’s Disease Mouse Models Displaying Metabolic Dysfunction.
PLoS One 8(12) (2013)

Hult Lundh S, Nilsson N, Soylu R, Kirik D and Petersén Å.
Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.
Human Molecular Genetics 22: 3485-3497 (2013)
 

Lilja Andersson P, Juth N, Petersén Å, Graff C and Edberg AE.
Ethical aspects of undergoing a predictive genetic testing for Huntington’s disease.
Nursing Ethics 20: 189-199 (2013)

2012

Lundh SH, Soylu R and Petersén Å.
Expression of Mutant Huntingtin in Leptin Receptor-Expressing Neurons Does Not Control the Metabolic and Psychiatric Phenotype of the BACHD Mouse.
PLoS One 7(12): 1-9 (2012)

Hagen N, Lundin S, O'Dell T and Petersén Å.
For Better or for Worse: Lifeworld, System and Family Caregiving for a Chronic Genetic Disease.
Culture Unbound 4: 537-557 (2012)

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D and Petersén Å.
Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
European Journal of Neuroscience 36(6): 2789-800 (2012)

Petersen Å and Gabery S.
Hypothalamic and limbic system changes in Huntington's disease.
Journal of Huntington's disease 1: 13-24 (2012)

Dupuis L, Petersen A and Weydt P.
Progranulin bridges energy homeostasis and fronto-temporal dementia.
Cell Metabolism 15: 269-270 (2012)

2011

Hult S*, Soylu R*, Björklund T, Belgardt BF, Mauer J, Brüning JC, Kirik D and Petersén Å.
Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.
Cell Metabolism 13: 428-439 (2011) *equal contribution

Piguet O, Petersén A, Yin Ka Lam B, Gabery S, Murphy K, Hodges JR and Halliday GM.
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. 
Annals of Neurology 69: 312-319 (2011)

Mikrouli E, Wörtwein G, Soylu R, Mathé AA and Petersén Å.
Increased numbers of orexin/hypocretin neurons in a genetic rat depression model.
Neuropeptides 45(6): 401-406 (2011)

Gil-Mohapel J, Brocardo PS, Smith R, Lagerkvist S, Li JY and Petersén Å.
Impaired nigrostriatal dopaminergic neurotransmission in Huntington’s disease: Insights from the R6/1 transgenic mouse model.
In H.T. Maldonado and I.M. Ortega (Eds.) Striatum: Anatomy, Functions and Role in Disease. New York, USA: Nova Publishers.

2010

Petersén Å
The Role of Hypothalamic and Neuroendocrine Changes in the Pathogenesis of Huntington’s Disease – Current Understanding and Implications for Future Treatments. 
European Neurological Review 5: 49–53 (2010)

Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G and Petersén Å.
Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses.
Acta Neuropathologica 120: 777-788 (2010)

Braunstein KE, Eschbach J, Ròna-Vörös K, Soylu R, Mikrouli E, Larmet Y, Rene F, Gonzalez de Aguilar JL, Loeffler JP, Müller HP, Bucher S, Kaulisch T, Niessen HG, Tillmanns J, Fischer K, Schwalenstocker B, Kassubek J, Pichler B, Stiller D, Petersen Å, Ludolph AC and Dupuis L.
A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons.  
Human Molecular Genetics 19: 4385-4398 (2010)

Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D and Petersén Å; The Huntington Study Group PREDICT-HD investigators.
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.  
Neurobiology of Disease 40: 531-543 (2010)

Hult S, Schultz K, Soylu R and Petersén Å.
Hypothalamic and Neuroendocrine Changes in Huntington's Disease.  
Current Drug Targets 11: 1237-1249 (2010)

Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C and Petersén Å.
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.  
European Journal of Neurology 17: 456- 460 (2010)

2009

Bode FJ, Stephan M, Wiehager S, Nguyen HP, Björkqvist M, von Hörsten S, Bauer A and Petersén Å.
Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington disease rat model.  
Behavioural Brain Research 205: 175-182 (2009)

Wiehager S, Beiderbeck D, Gruber S, El Khoury A, Waamsteker J, Neumann I, Mathé A* and Petersén Å*.
Increased levels of cocaine and amphetamine regulated transcript (CART) in two animal models of depression and anxiety.  
Neurobiology of Disease 34: 375-380 (2009) *equal contribution

Pouladi M, Graham RK, Karasinska JM, Xie Y, Dar Santos R, Petersén Å and Hayden MR.
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin.
Brain 132 (4): 919-932 (2009)

Schultz K, Wiehager S, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson CF and Petersén Å.
Reduced CSF CART in dementia with Lewy bodies.  
Neuroscience Letters 453: 104-106 (2009)

Petersén Å, Hult S and Kirik D.
Huntington’s disease - new perspectives based on neuroendocrine changes in rodent models.  
Neurodegenerative Diseases 6: 154-164 (2009)

Petersén Å and Lundberg L.
Neuroleptic malignant syndrome - rare diagnosis with high mortality.  
Läkartidningen 106: 1273-1276 (2009)

Brundin L, Björkqvist M, Träskman-Bendz L and Petersén Å.
Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt.  
Journal of Affective Disorders 113: 179-182 (2009)

Petersén Å, Wörtwein G, Gruber SH, El-Khoury A and Mathé AA.
Nortriptyline mediates behavioral effects without affecting hippocampal cytogenesis in a genetic rat depression model.  
Neuroscience Letters 451(2): 148-151 (2009)
 

2008

Bode F, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, Bonin M, Nguyen HP, Riess O, Bauer A, Sjoberg C, Petersén Å and von Horsten S.
Sex differences in a transgenic rat model of Huntington’s disease: decreased 17 b-estradiol levels correlate with reduced number of DARPP-32 neurons in males.  
Human Molecular Genetics 17(17): 2595-2609 (2008)

Petersén Å, Wörtwein G, Gruber S and Mathé A.
Escitalopram reduces increased hippocampal cytogenesis in genetically depressed rat.  
Neuroscience letters 436(3): 305-308 (2008)

Bacos K, Björkqvist M, Petersén Å, Luts L, Maat-Schieman M, Roos R, Sundler F, Brundin P, Mulder H and Wierup N.
Islet b-cell area and hormone expression are unaltered in Huntington's Disease.  
Histochemistry and Cell Biology 129: 623-629 (2008)

Brundin L, Björkqvist M, Träskman-Bendz L and Petersén Å.
Cocaine and amphetamine regulated transcript (CART) in a cohort of suicide attempters.  
Psychiatry Research 158(2): 117-122 (2008)

Wood N, Goodman AOG, van der Burg J, Gazeau V, Brundin P, Björkqvist M, Petersén Å, Tabrizi SJ, Barker RA and Morton AJ.
Increased thirst and drinking in Huntington’s disease and the R6/2 mouse.  
Brain Research Bulletin 76: 70-79 (2008)

Schultz K, Träskman-Bendz L and Petersén Å.
Transthyretin in cerebrospinal fluid from suicide attempters.  
Journal of Affective Disorders 109: 205-208 (2008)

Araújo IM, Gil J, Carreira BP, Mohapel P, Petersén Å, Pinheiro PS, Soulet D, Bahr BA, Brundin P and Carvalho CM.
Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus.  
Journal of Neurochemistry 105: 666-676 (2008)

van der Burg JMM, Bacos K, Wood N, Lindqvist A, Wierup N, Wamsteeker J, Deierborg-Olsson T, Mulder H, Erlanson-Albertsson C, Morton J, Brundin P, Björkqvist M* and Petersén Å*.
Increased metabolism in the R6/2 mouse model of Huntington's disease.  
Neurobiology of Disease 29: 41-51 (2008) *equal contribution 

2007

Dalrymple A, Wild E, Joubert R, Sathasivam K, Björkqvist M, Petersén Å, Isaacs J, Kristiansten M, Bates G, Leavitt B, Keir G, Ward M and Tabrizi SJ.
Proteomic profiling of plasma in Hungtinton's disease reveals neuroinflammatory acivation and biomarker candidates.  
Journal of Proteome Research 6: 2833-2840 (2007)

Brundin L, Petersén Å, Björkqvist M and Träskman-Bendz L.
Orexin and psychiatric symptoms in suicide attempters.  
Journal of Affective Disorders 100: 259-263 (2007)

Björkqvist M, Leavitt B, Nielsen J, Landwehrmeyer B, Ecker D, Mulder H, Brundin P and Petersén Å.
Cocaine and amphetamine regulated transcript is increased in Huntington disease.  
Movement Disorders 22: 1952-1954 (2007)

Brundin L, Björkqvist M, Petersén Å and Träskman-Bendz L.
Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.  
European Neuropsychopharmacology 17: 573-579 (2007)

Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersen Å, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR and Leavitt BR.
Testicular degeneration in Huntington disease.  
Neurobiology of Disease 26: 512-520 (2007)
 

2006

Petersén Å and Björkqvist M.
Hypothalamic-endocrine aspects in Huntington’s disease.  
Review. European Journal of Neuroscience 24: 961-967 (2006)

Björkqvist M*, Petersén Å*, Nielsen J, Ecker D, Mulder H, Hayden M, Landwehrmeyer B, Brundin P and Leavitt B.
Cerebrospinal fluid levels of orexin-A levels are not a useful biomarker for Huntington disease.  
Clinical Genetics 70: 78-79 (2006) *equal contribution

Björkqvist M, Petersén Å, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P and Mulder H.
Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington’s disease.  
Human Molecular Genetics 15: 1713-1721 (2006)

Winkler C, Gil JMAC, Araújo IM, Rieß O, Skripuletz I, von Hörsten S and Petersén Å.
Normal sensitivity to excitotoxicity in a transgenic Huntington’s disease rat.  
Brain Research Bulletin 69: 306-310 (2006)

Gawlik KI, Li J-Y, Petersén Å and M Durbeej.
Laminin 1 chain improves laminin 2 chain deficient peripheral neuropathy.  
Human Molecular Genetics 15: 2690-2700 (2006)
 

2005

Petersén Å, Gil J, Maat-Schieman MLC, Björkqvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlén P, Li JY, Roos RAC, Sundler F, Mulder H and Brundin P
Orexin loss in Huntington’s disease.  
Human Molecular Genetics 14: 39-47 (2005). [Commentary by: Khamsi, R., Nature 432:288 (2005); and by Hurtley, S., Science 307:483 (2005)]

Puschban Z, Stefanova N, Petersén Å, Winkler C, Brundin P, Poewe IW and Wenning GP.
Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.  
Brain Research Bulletin 68: 54-58 (2005)

Gil JM, Mohapel P, Araujo IM, Popovic N, Li JY, Brundin P and Petersen Å.
Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.  
Neurobiology of Disease 3: 744-751 (2005)

Petersén Å, Stewénius Y, Björkqvist M and Gisselsson D.
Euploidy in somatic cells from R6/2 transgenic Huntington’s disease mice.  
BMC Cell Biology 6: 34 (2005)

Smith R, Petersén Å, Bates GP, Brundin P and Li JY.
Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.  
Neurobiology of Disease 20: 673-84 (2005)

Björkqvist M, Fex M, Renstrom E, Wierup N, Petersén Å, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P and Mulder H.
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.  
Human Molecular Genetics 14: 565-574 (2005)

Karlsson J, Petersén Å, Gidö G, Wieloch T and Brundin P.
Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft reccipient.  
Cell Transplantation 14: 301-309 (2005)

Araujo IM, Xapelli S, Gil JM, Mohapel P, Petersén Å, Pinheiro PS, Malva JO, Bahr BA, Brundin P and Carvalho CM.
Proteolysis of NR2B by calpain in the hippocampus of epileptic rats.  
Neuroreport 16: 393-396 (2005)

Papalexi E, Persson A, Björkqvist M, Petersén Å, Woodman B, Bates GP, Sundler F, Mulder H, Brundin P and Popovic N.
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington’s disease.  
European Journal of Neuroscience 22: 1541-1546 (2005)

Popovic N, Petersén Å, Li YJ and Brundin P.
Stem Cells and Huntington’s Disease. 
Baudry: Synaptic Plasticity 17: 361-392 (2005)

2004

Gil MAC J, Leist M, Popovic N, Brundin P and Petersén Å.
Asialoerythropoetin is not effective in the R6/2 line of Huntington’s disease mice.  
BMC Neuroscience 5: 17 (2004)
 

2002

Petersén Å, Puschban Z, Lotharius J, NicNiocaill B, Wiekop B, O´Connor, WT and Brundin P.
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.  
Neurobiology of Disease 11: 134-146 (2002)

Petersén Å, Chase K, Puschban Z, DiFiglia M, Brundin P and Aronin N.
Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.  
Experimental Neurology 175: 297-300 (2002)

Petersén Å and Brundin P.
Huntington's Disease: the mystery unfolds? 
International Review of Neurobiology 53: 315-339 (2002)

2001

Petersén Å, Hansson O, Puschban Z, Sapp E, Romero N, Castilho RF, Sulzer D, Rice M, DiFiglia M, Przedborski S and Brundin P.
Mice transgenic for exon 1 of the Huntington gene display reduced sensitivity to neurotoxicity induced by intrastriatal injections of dopamine and 6-hydroxydopamine.  
European Journal of Neuroscience 14: 1-13 (2001)

Petersén Å, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P and Sulzer D.
Expanded CAG repeats in exon 1 of the Huntington's Disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration.  
Human Molecular Genetics 10: 1-12 (2001)

Petersén Å, Behr GG, Larsen KE, Romero N, Przedborski S, Brundin P and Sulzer D.
Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death.
Brain Research Bulletin 56: 331-335 (2001)

Gisselsson D, Jonson T, Petersén Å, Strombeck B, Dal Cin P, Hoglund M, Mitelman F, Mertens F and Mandahl N.
Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors.  
Proceedings of the National Academy of Sciences USA 98: 12683-12688 (2001)

Petersén Å, Hansson O and Brundin P.
Huntingtons sjukdom - ännu ett galet protein?  
In Swedish. Läkartidningen 50: 5756-5761 (2001)
 

2000

Petersén Å, Castilho RF, Hansson O, Wieloch T and Brundin P.
Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured neurons.  
Brain Research 857: 20-29 (2000)

Mundt-Petersén U, Petersén Å, Emgård M, Dunnett SB and Brundin P.
Caspase inhibition increases embryonic striatal graft survival.  
Experimental Neurology 164:112-120 (2000)

Petersén Å, Hansson O, Emgård M and Brundin P.
Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell-line derived neurotrophic factor.  
Cell Transplantation 9: 577-584 (2000)

Brundin P, Karlsson J, Emgård M, Kaminski Schierle GS, Hansson O, Petersén Å and Castilho RF.
Improving the survival of grafted dopaminergic neurons: a review over current approaches.  
Cell Transplantation 9: 179-195 (2000)
 

1999

Hansson O, Petersén Å, Leist M, Nicotera P, Castilho RF and Brundin P.
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.  
Proceedings of the National Academy of Sciences USA 96: 8727-8732 (1999)

Petersén Å and Brundin P.
Effect of CNTF and calcium-ionophore A23187-induced death in cultured embryonic stratal neurons.  
Experimental Neurology 160: 402-412 (1999)

Petersén Å, Emgård M and Brundin P.
Impact of a preceding excitotoxic lesion and treatment with ciliary neurotrophic factor on striatal graft survival.  
Brain Research Bulletin 50: 275-281 (1999)

Petersén Å, Mani K and Brundin P.
Recent advances in the pathogenesis of Huntington's disease.  
Experimental Neurology 157: 1-18 (1999)

Brundin P, Petersén Å and Hansson O.
Graft survival.  
Journal of Neurosurgery 90: 804-806 (1999)

Site overview